HomeCompareABC vs PFE

ABC vs PFE: Dividend Comparison 2026

ABC yields 1.08% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $20.2K in total portfolio value· pulled ahead in Year 9
10 years
ABC
ABC
● Live price
1.08%
Share price
$179.98
Annual div
$1.94
5Y div CAGR
34.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.8K
Annual income
$2,940.21
Full ABC calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — ABC vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABC
Annual income on $10K today (after 15% tax)
$91.62/yr
After 10yr DRIP, annual income (after tax)
$2,499.18/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $20,629.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABC + PFE for your $10,000?

ABC: 50%PFE: 50%
100% PFE50/50100% ABC
Portfolio after 10yr
$41.0K
Annual income
$15,075.37/yr
Blended yield
36.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABC right now

ABC
Analyst Ratings
20
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$171.00
-5.0% upside vs current
Range: $150.00 — $190.00
Altman Z
4.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABC buys
3
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Tommy Tuberville🏛 Senate$ABC▼ Sell$15,001 - $50,0002022-01-21
Tommy Tuberville🏛 Senate$ABC▼ Sell$15,001 - $50,0002022-01-21
Michael McCaul🏢 House$ABC▲ Buy$50,001 - $100,0002021-03-01
Michael McCaul🏢 House$ABC▲ Buy$50,001 - $100,0002021-03-01
Gilbert Cisneros🏢 House$ABC▼ Sell$1,001 - $15,0002019-05-09
Pete Sessions🏢 House$ABC▼ Sell$15,001 - $50,0002017-11-27
Thomas Suozzi🏢 House$ABC▼ Sell$15,001 - $50,0002017-01-05
Pete Sessions🏢 House$ABC▲ Buy$15,001 - $50,0002015-07-31
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABCPFE
Forward yield1.08%6.20%
Annual dividend / share$1.94$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR34.4%13.2%
Portfolio after 10y$30.8K$51.1K
Annual income after 10y$2,940.21$27,210.54
Total dividends collected$9.6K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$171.00$27.50

Year-by-year: ABC vs PFE ($10,000, DRIP)

YearABC PortfolioABC Income/yrPFE PortfolioPFE Income/yrGap
1$10,845$144.87$9,161$701.38+$1.7KABC
2$11,801$197.34$8,610$859.79+$3.2KABC
3$12,897$269.74$8,366$1,081.25+$4.5KABC
4$14,170$370.27$8,483$1,405.66+$5.7KABC
5$15,673$510.99$9,084$1,907.24+$6.6KABC
6$17,480$709.92$10,418$2,732.78+$7.1KABC
7$19,698$994.53$13,007$4,193.56+$6.7KABC
8$22,485$1,407.72$18,010$7,005.87+$4.5KABC
9← crossover$26,077$2,018.33$28,216$12,979.89$2.1KPFE
10$30,843$2,940.21$51,081$27,210.54$20.2KPFE

ABC vs PFE: Complete Analysis 2026

ABCStock

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Full ABC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ABC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABC vs SCHDABC vs JEPIABC vs OABC vs KOABC vs MAINABC vs JNJABC vs MRKABC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.